147
Participants
Start Date
July 27, 2021
Primary Completion Date
October 18, 2024
Study Completion Date
October 18, 2024
Doravirine 100 Mg
Participants received a 100 mg tablet by mouth daily with or without food.
Integrase strand transfer inhibitors
INSTIs were acquired through the standard of care locally.
Tenofovir alafenamide/emtricitabine
NRTIs (TAF/FTC) were acquired through the standard of care locally.
tenofovir disproxil fumarate/emtricitabine
NRTIs (TDF/FTC) were acquired through the standard of care locally.
Weill Cornell Chelsea CRS (7804), New York
Columbia Physicians and Surgeons (P&S) CRS (30329), New York
Weill Cornell Upton CRS (7803), New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester
Penn Therapeutics CRS (6201), Philadelphia
Whitman-Walker Institute, Inc. CRS (31791), Washington D.C.
Johns Hopkins University CRS (201), Baltimore
Greensboro CRS (3203), Greensboro
Chapel Hill CRS (3201), Chapel Hill
The Ponce de Leon Center CRS (5802), Atlanta
Alabama CRS (31788), Birmingham
Vanderbilt Therapeutics (VT) CRS (3652), Nashville
Ohio State University CRS (2301), Columbus
Case CRS (2501), Cleveland
Cincinnati CRS (2401), Cincinnati
Northwestern University CRS (2701), Chicago
Washington University Therapeutics (WT) CRS (2101), St Louis
Houston AIDS Research Team CRS (31473), Houston
University of Colorado Hospital CRS (6101), Aurora
UCLA CARE Center CRS (601), Los Angeles
Harbor-UCLA CRS (603), Torrance
UCSD Antiviral Research Center CRS (701), San Diego
Ucsf Hiv/Aids Crs (801), San Francisco
University of Washington Positive Research CRS (1401), Seattle
Massachusetts General Hospital (MGH) CRS (101), Boston
Brigham and Women's Hosp. ACTG CRS (107), Boston
New Jersey Medical School Clinical Research Center CRS (31786), Newark
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK